» Articles » PMID: 14998922

Roles of P63 in the Diethylstilbestrol-induced Cervicovaginal Adenosis

Overview
Journal Development
Specialty Biology
Date 2004 Mar 5
PMID 14998922
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Women exposed to diethylstilbestrol (DES) in utero develop abnormalities, including cervicovaginal adenosis that can lead to cancer. We report that transient disruption of developmental signals by DES permanently changes expression of p63, thereby altering the developmental fate of Müllerian duct epithelium. The cell fate of Müllerian epithelium to be columnar (uterine) or squamous (cervicovaginal) is determined by mesenchymal induction during the perinatal period. Cervicovaginal mesenchyme induced p63 in Müllerian duct epithelium and subsequent squamous differentiation. In p63(-/-) mice, cervicovaginal epithelium differentiated into uterine epithelium. Thus, p63 is an identity switch for Müllerian duct epithelium to be cervicovaginal versus uterine. P63 was also essential for uterine squamous metaplasia induced by DES-exposure. DES-exposure from postnatal day 1 to 5 inhibited induction of p63 in cervicovaginal epithelium via epithelial ERalpha. The inhibitory effect of DES was transient, and most cervicovaginal epithelial cells recovered expression of p63 by 2 days after discontinuation of DES-treatment. However, some cervicovaginal epithelial cells failed to express p63, remained columnar and persisted into adulthood as adenosis.

Citing Articles

Decoding Müllerian Duct Epithelial Regionalization.

Jia S, Zhao F Mol Reprod Dev. 2025; 92(2):e70018.

PMID: 39994938 PMC: 11850963. DOI: 10.1002/mrd.70018.


Uterine organoids reveal insights into epithelial specification and plasticity in development and disease.

Rizo J, Ahmad V, Pru J, Winuthayanon S, Challa S, Kim T Proc Natl Acad Sci U S A. 2025; 122(5):e2422694122.

PMID: 39883834 PMC: 11804710. DOI: 10.1073/pnas.2422694122.


Estrogen receptor alpha regulates uterine epithelial lineage specification and homeostasis.

Rizo J, Davenport K, Winuthayanon W, Spencer T, Kelleher A iScience. 2023; 26(9):107568.

PMID: 37622003 PMC: 10445454. DOI: 10.1016/j.isci.2023.107568.


Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome.

Hernandez-Jerez A, Adriaanse P, Aldrich A, Berny P, Coja T, Duquesne S EFSA J. 2023; 21(2):e07744.

PMID: 36818642 PMC: 9926893. DOI: 10.2903/j.efsa.2023.7744.


Menstural function preservation treatment of a primary vaginal clear cell carcinoma with ovarian transposition and vaginal brachytherapy.

Vlachos D, Protopapas A, Vlachos G, Sarris K, Sotiropoulou M, Terzi M Gynecol Oncol Rep. 2021; 36:100764.

PMID: 33912644 PMC: 8063755. DOI: 10.1016/j.gore.2021.100764.